NorthStrive Biosciences plans FACS study for EL-22 probiotic candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
July 10, 2026 7:30 AM EDTIndependent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd.
Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists
NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive Biosciences), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (PMGC or the Company), today announced plans to initiate an... More
